Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CEO Sean Duffy sold 14,960 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.87, for a total transaction of $327,175.20. Following the sale, the chief executive officer directly owned 382,594 shares of the company’s stock, valued at approximately $8,367,330.78. This trade represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Omada Health Trading Up 4.3%
Shares of NASDAQ:OMDA traded up $0.84 during midday trading on Monday, reaching $20.50. 961,447 shares of the company were exchanged, compared to its average volume of 1,250,359. The business’s fifty day moving average is $22.63 and its two-hundred day moving average is $17.97. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92. The stock has a market cap of $1.26 billion, a PE ratio of 410.00 and a beta of 1.86.
Omada Health (NASDAQ:OMDA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. As a group, sell-side analysts expect that Omada Health, Inc. will post 0.09 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on OMDA shares. Robert W. Baird boosted their target price on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group lifted their price objective on Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Omada Health in a research report on Friday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a report on Friday, August 7th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.67.
Get Our Latest Stock Report on OMDA
About Omada Health
Omada Health, Inc is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines clinical care, health coaching, connected devices, digital tools and personalized support to help members improve health outcomes and manage conditions over time.
The company’s offerings address areas including diabetes, hypertension, weight health and musculoskeletal conditions. Omada’s programs are designed to support prevention and ongoing care through services such as remote monitoring, personalized health guidance, educational content and access to healthcare professionals.
Omada primarily serves members through employers, health plans and healthcare organizations in the United States.
Featured Articles
- Five stocks we like better than Omada Health
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
